Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Brepocitinib on QTc Interval in Healthy Volunteers
NCT03656952Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of brepocitinib in psoriasis, psoriatic arthritis (PsA), ulcerative colitis (UC) and 3 more (6 arms), sponsored by Pfizer. Primary endpoint: QTc change from baseline following PF-06700841 treatment. Started Sep 2018; status: completed.
02
Drugs
brepocitinib
03
Conditions
psoriasispsoriatic arthritis (PsA)ulcerative colitis (UC)Crohn's diseasesystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03656952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656952.